| March 30, 2008 |
| April 3, 2008 |
| July 2003 |
| March 2008 (final data collection date for primary outcome measure) |
| Clinical success will be defined as no occurrences of any of the following events: recurrent pulmonary embolism, IVC occlusion or filter embolization. [ Time Frame: 6 months follow-up ] [ Designated as safety issue: Yes ] |
| Same as current |
| Complete list of historical versions of study NCT00654979 on ClinicalTrials.gov Archive Site |
| The proportion of patients with successful deployment of the filter will be calculated and presented with a 95% exact confidence interval. [ Time Frame: 3 and 6 months follow-up ] [ Designated as safety issue: Yes ] |
| Same as current |
| |
| A Pivotal Study to Evaluate the Safety and Effectiveness of RMT Medical Technology's SafeFlo® Vena Cava Filter |
| A Pivotal Study to Evaluate the Safety and Effectiveness of RMT Medical Technology's SafeFlo® Vena Cava Filter |
To determine the safety and effectiveness of the SafeFlo filter for permanent protection against pulmonary emboli. All patients will be selected to receive the filter according to the stated inclusion / exclusion criteria after consultation between the attending physician and interventional radiologist. Patients with a permanent implantation will be followed for up to 6 months. Clinical success will be defined as no occurrences of any of the following events: recurrent pulmonary embolism, IVC occlusion or filter embolization. The proportion of permanent filter patients considered to be a clinical success will be the primary efficacy parameter. |
| |
| |
| Interventional |
| Prevention, Open Label, Historical Control, Single Group Assignment, Safety/Efficacy Study |
| Pulmonary Embolism |
| Device: SafeFlo IVC Filter |
| |
| |
| |
| Active, not recruiting |
| 117 |
|
| March 2008 (final data collection date for primary outcome measure) |
Inclusion Criteria:
Traditional indications for vena cava filter in patients with established DVT or PE, including (40):
Extended indications for vena cava filter placement in patients with established DVT or PE, including the following (31, 40):
- Large free-floating thrombus in the iliac vein or IVC;
- Following massive PE in which recurrent emboli may prove fatal;
- During/after surgical or transcatheter embolectomy;
- Filter placement in high-risk trauma and orthopedic patients:
High risk trauma or orthopedic patients who cannot receive anticoagulation because of increased bleeding risk, and have one or more of the following injury patterns (31, 40):
- Severe closed head injury (GCS < 8);
- Incomplete spinal cord injury with para or quadriplegia;
- Complex pelvic fractures with associated long-bone fractures;
- Multiple long bone fractures.
- Patients undergoing long-term immobilization (e.g., ICU or Surgical oncology)
Exclusion Criteria:
- All patients under 18 years of age.
- All patients undergoing emergency procedures.
- All patients with abnormal IVC anatomy or pathology of the IVC such as thrombosis or tumor which prevent safe filter implantation.
- All patients with an IVC diameter which precludes oversizing of the filter platform.
- All patients with active infection / bacteremia.
- All patients with sensitivity to contrast media.
- Uncorrectable severe coagulopathy (e.g., patients with liver or multisystem failure).
|
| Both |
| 18 Years and older |
| No |
| Contact information is only displayed when the study is recruiting subjects |
| United States, Austria, Greece, Israel, South Africa, United Kingdom |
| |
| NCT00654979 |
| Aaron Feldman, CEO, RMT Medical Technologies, Ltd. |
| SFF-104 |
| RMT Medical Technologies, Ltd. |
|
|
| RMT Medical Technologies, Ltd. |
| April 2008 |